Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Announces U.S. FDA Approval for TRIKAFTA (Elexacaftor/tezacaftor/ivacaftor and Ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
Vertex Insider Sold Shares Worth $1,060,932, According to a Recent SEC Filing
Stifel Maintains Vertex(VERX.US) With Buy Rating, Raises Target Price to $58
